Silence Therapeutics' divesiran shows strong Phase 2 signals in polycythemia vera
TL;DR Summary
In a 48-patient Phase 2 study for the rare blood cancer polycythemia vera, Silence Therapeutics' RNA drug divesiran achieved a clinical response in 88% of treated patients versus 19% on placebo, suggesting robust efficacy and potential competitiveness with Takeda's near-approval therapy.
- Silence Therapeutics aims at Takeda with new data in rare blood cancer STAT
- Silence brings the noise to Takeda with phase 2 blood cancer win Fierce Biotech
- Silence spells out Phase 2 success for gene-silencing drug in rare blood cancer Endpoints News
- Divesiran Meets Primary Response End Point in Phlebotomy-Dependent Polycythemia Vera onclive.com
- Silence posts mid-stage polycythemia vera win, preps for Phase III FirstWord Pharma
Reading Insights
Total Reads
0
Unique Readers
6
Time Saved
2 min
vs 2 min read
Condensed
89%
389 → 41 words
Want the full story? Read the original article
Read on STAT